Shares of YY Inc (NYSE:YY) have earned a consensus rating of “Buy” from the nine analysts that are presently covering the company. Three research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock…
Standard & Poor’s Ratings Services said its ratings on Covidien plc (NYSE:COV) including its ‘A’ corporate credit rating and issue-level ratings, remain on CreditWatch with positive implications. Covidien plc (NYSE:COV) belongs to Healthcare sector. Its net profit margin is 14.50% and weekly performance is -11.55%. On last trading day company shares ended up $82.20. Covidien…
On 16 October iBio, Inc. (NYSEMKT:IBIO) confirmed, in response to shareholder and media inquiries: (i) the applicability of its issued U.S. iBioLaunch” platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus, and (ii) that iBio has an ongoing relationship with Caliber Biotherapeutics LLC reflected by a…
On 16 October Sify Technologies Limited (NASDAQ:SIFY) announced its consolidated results under International Financial Reporting Standards (IFRS) for the second quarter of fiscal year 2014-15. Revenue for the quarter ended September 30, 2014 was INR 3160 million, an increase of 26% over the same quarter last year. Sify Technologies Limited (NASDAQ:SIFY) belongs to Technology sector….
On 14 October Sabre Corporation (NASDAQ:SABR) and PriceTravel Holding announced a renewed and expanded technology agreement. Sabre will continue providing software solutions and IT support to power PriceTravel Holding websites visited by 1.2 million consumers each month. Sabre will also continue to be their main source of fares and availability data for more than 400…
Alnylam Pharmaceuticals, Inc (ALNY) revealed encouraging initial results from an ongoing phase II open-label extension study (n=27) on one of its most important pipeline candidates, patisiran (ALN-TTR02). The stock soared almost 19% following the announcement. Patisiran, one of the most advanced candidates at Alnylam, is a subcutaneously administrated ribo nucleic acid interference (RNAi) therapeutic being…
